Erik Pulkstenis

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

Bruce E. Sands, Jingjing Chen, Brian G. Feagan et al. · Gastroenterology · 2017 · 277 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

Mixed Effects Logistic Regression Models for Longitudinal Binary Response Data with Informative Drop-Out

Allen R. Kunselman, Erik Pulkstenis, J. Richard Landis · Biometrics · 1998 · 183 citations

Public Health, Biostatistics, Causal Inference +16

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

David R. Nelson, Yves Benhamou, Wan‐Long Chuang et al. · Gastroenterology · 2010 · 92 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

Alexander Thompson, Keyur Patel, Wan‐Long Chuang et al. · Gut · 2011 · 88 citations

Medicine, Endocrinology, Infectious Diseases +16

Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C†‡

Stefan Zeuzem, Eric M. Yoshida, Yves Benhamou et al. · Hepatology · 2008 · 80 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17